Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Breast Cancer Res Treat. 2011 Dec 27;132(3):1063–1072. doi: 10.1007/s10549-011-1928-x

Figure 3. Inconsistent in vivo effects of VS treatment in peripheral blood mononuclear cells (PBMCs) derived from ER-positive and ER-negative patients.

Figure 3

A. Peripheral blood was collected from patients #001 and #010 prior to the administration of VS on Day1 (Pre-Rx) and Day 2 (post-second dose) then 4 hours after dosing on Day 2 (post-third dose). PBMCs were separated by Ficoll Hypaque and cell lysates were prepared. Immunoblot analyses were performed for the acetylated-K69 of hsp90, hsp90, hsp70, and AKT on the total cell lysates. The expression levels of β-actin in the lysates served as the loading control. B. Peripheral blood was collected from patients #051, #052, #053 and #054 at the indicated time points and processed as in (A). Immunoblot analyses were performed for the acetylated-K69 of hsp90, hsp90, hsp70 and p21 on the total cell lysates. The expression levels of β-actin in the lysates served as the loading control.